Adial Pharmaceuticals
ADIL
9 hedge funds and large institutions have $1.02M invested in Adial Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
25% less funds holding
Funds holding: 12 → 9 (-3)
61% less capital invested
Capital invested by funds: $2.61M → $1.02M (-$1.58M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$201K |
| 2 |
Jane Street
New York
|
-$105K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$91K |
| 4 |
Two Sigma Investments
New York
|
-$87K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $494K | -$23.9K | -16 | -3% |
|
2
BlackRock
New York
| $346K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $131K | – | – | – |
|
4
Brown Advisory
Baltimore,
Maryland
| $44K | – | – | – |
|
5
UBS Group
Zurich,
Switzerland
| $3K | -$4.47K | -3 | -50% |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $3K | +$4.47K | +3 | New |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | -$1.49K | -1 | -50% |
|
8
Morgan Stanley
New York
| $1K | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
10
Millennium Management
New York
| – | -$201K | -94 | Closed |
|
|
11
Jane Street
New York
| – | -$105K | -49 | Closed |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$91K | -42 | Closed |
|
|
13
Two Sigma Investments
New York
| – | -$87K | -41 | Closed |
|
ADIL Hedge Fund Activity: Q2 2019 in Review
9 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2019, worth a combined $1.02M — down 61% from $2.61M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ADIL and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $4.47K. The largest seller was Millennium Management, exiting entirely with an estimated $201K sold.
- 9 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2019, down from 12 in Q1 2019.
- Funds reported $1.02M of Adial Pharmaceuticals stock for Q2 2019, down 61% quarter-over-quarter.
- 1 fund opened new Adial Pharmaceuticals positions in Q2 2019 and 4 closed out, a net change of -3 holders.
- The largest Adial Pharmaceuticals buyer in Q2 2019 was Deutsche Bank, an estimated $4.47K added.
- The largest Adial Pharmaceuticals seller in Q2 2019 was Millennium Management, an estimated $201K sold.
Based on aggregated 13F filings for Q2 2019.